Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain.

De Salas-Cansado M, Olivares JM, Alvarez E, Carrasco JL, Barrueta A, Rejas J.

Clinicoecon Outcomes Res. 2012;4:157-68. doi: 10.2147/CEOR.S31102.

2.

Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.

De Salas-Cansado M, Álvarez E, Olivares JM, Carrasco JL, Ferro MB, Rejas J.

Soc Psychiatry Psychiatr Epidemiol. 2013 Jun;48(6):985-96. doi: 10.1007/s00127-012-0606-6.

PMID:
23086587
3.
4.

A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.

de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, Rejas J.

Pain Med. 2012 May;13(5):699-710. doi: 10.1111/j.1526-4637.2012.01375.x.

PMID:
22594706
5.

An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.

de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, González-Gómez FJ, Ruiz L, Rejas J.

Prim Care Diabetes. 2012 Dec;6(4):303-12. doi: 10.1016/j.pcd.2012.03.001.

PMID:
22595032
6.

Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.

Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G.

Eur J Health Econ. 2010 Feb;11(1):35-44. doi: 10.1007/s10198-009-0160-7.

7.

Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors.

Álvarez E, Olivares JM, Carrasco JL, López-Gómez V, Rejas J.

Ann Gen Psychiatry. 2015 Jan 22;14(1):2. doi: 10.1186/s12991-014-0040-0.

9.

Pregabalin versus sertraline in generalized anxiety disorder. An open label study.

Cvjetkovic-Bosnjak M, Soldatovic-Stajic B, Babovic SS, Boskovic K, Jovicevic M.

Eur Rev Med Pharmacol Sci. 2015;19(11):2120-4.

10.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

11.

A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.

Peveler R, Kendrick T, Buxton M, Longworth L, Baldwin D, Moore M, Chatwin J, Goddard J, Thornett A, Smith H, Campbell M, Thompson C.

Health Technol Assess. 2005 May;9(16):1-134, iii.

12.

Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective.

Darbà J, Kaskens L, Pérez C, Álvarez E, Navarro-Artieda R, Sicras-Mainar A.

Adv Ther. 2014 Jan;31(1):1-29. doi: 10.1007/s12325-013-0088-2. Review.

PMID:
24390901
13.

Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.

Bereza BG, Machado M, Einarson TR.

Clin Ther. 2009 Jun;31(6):1279-308. doi: 10.1016/j.clinthera.2009.06.004. Review.

PMID:
19695395
14.

A cost-consequence analysis of pregabalin versus usual care in the symptomatic treatment of refractory low back pain: sub-analysis of observational trial data from orthopaedic surgery and rehabilitation clinics.

Morera-Domínguez C, Ceberio-Balda F, Flórez-García M, Masramón X, López-Gómez V.

Clin Drug Investig. 2010;30(8):517-31. doi: 10.2165/11536280-000000000-00000.

PMID:
20513162
15.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
16.

The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study.

Rovira J, Albarracin G, Salvador L, Rejas J, Sánchez-Iriso E, Cabasés JM.

Community Ment Health J. 2012 Jun;48(3):372-83. doi: 10.1007/s10597-012-9503-4.

PMID:
22484993
17.

Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.

Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder MH.

Curr Med Res Opin. 2008 Oct;24(10):2805-13. doi: 10.1185/03007990802336780 .

PMID:
18755054
18.

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy.

Mencacci C, Di Sciascio G, Katz P, Ripellino C.

Clinicoecon Outcomes Res. 2013;5:87-99. doi: 10.2147/CEOR.S39492.

19.

Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice.

Ruiz MA, Álvarez E, Carrasco JL, Olivares JM, Pérez M, Rejas J.

Drug Des Devel Ther. 2015 Aug 6;9:4329-40. doi: 10.2147/DDDT.S88238.

20.

Clinical and resource utilization patterns in patients with refractory neuropathic pain prescribed pregabalin for the first time in routine medical practice in primary care settings in Spain.

Pérez C, Navarro A, Saldaña MT, Masramón X, Pérez M, Rejas J.

Pain Med. 2013 Dec;14(12):1954-63. doi: 10.1111/pme.12276.

PMID:
24330229

Supplemental Content

Support Center